eccogene glp-1 Non‐clinical and first‐in‐human characterization of ECC5004/AZD5004, a novel once‐daily, oral small‐molecule GLP‐1 receptor agonist - Haggag - 2025 - Diabetes, Obesity and Metabolism 9 Companies Developing Next-Generation GLP-1
Pay in 4 interest-free payments of $6.79 Learn more
Shipping Estimate
USA
- USA
- CAN
- USA
- CAN
Ships within 48 hours · Estimated delivery Jul 31 - Aug 5












00002-5/asset/c86f6f00-7fc9-46f8-8db8-efb843af04ef/main.assets/fx1.jpg)


![Literature Review] Structural Biophysics-Guided Computational Design of Semaglutide Analogues to Enhance GLP-1R Activation](https://moonlight-paper-snapshot.s3.ap-northeast-2.amazonaws.com/arxiv/structural-biophysics-guided-computational-design-of-semaglutide-analogues-to-enhance-glp-1r-activation-1.png)











